MTOR and plasma cell myeloma: Kinase and proteasome inhibitor combination treatments are currently being studied in myeloma, including combining aurora-A, Chk1, CDK, Akt, MEK, mTOR, PI3K, and p38 inhibitors with bortezomib [57, 58].